Fernanda Raquel Da Silva Andrade Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal). Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Fernanda Raquel Da Silva Andrade Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal).
Her research interests are based on the development of formulations, namely nanoparticles, for the administration of drugs and biopharmaceuticals (peptides, proteins and genetic material) for the treatment of challenging diseases. Also has experience on study the effects of drugs and delivery systems on cancer stem cells and on the development and use of cell-culture models, animal models, and ex vivo models for drug absorption studies through the pulmonary, intestinal, and blood brain barrier. Her major objective relies on the development of multifunctional drug delivery systems with improved characteristics such as increased therapeutic index and targeted delivery, allowing and efficient and safe treatment of challenging diseases like cancer or infectious diseases, with the ultimate goal of personalized medicine. Her research work at different projects and collaborations with a variety of research groups from different countries have resulted in the authorship of two patents, several research and review papers, as well as book chapters.
Projects Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. IP: - Collaborators: Sandra Mancilla Zamora, Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. , Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 116160 Reference: PI18/00871 Duration: 01/01/2019 - 30/06/2022 SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. IP: - Collaborators: SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Olga Sánchez- Maroto Carrizo, Sandra Mancilla Zamora, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Belen Garcia Prats, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 649580 Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018 Duration: 01/04/2019 - 30/09/2023 Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos IP: Simon Schwartz Navarro Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI17/02242 Duration: 01/01/2018 - 31/12/2020 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
